Background: The relationship between isolated hepatitis B virus (HBV) core antibody (sole HBcAb) and liver disease in HIV+ patients is unclear. We determined if sole HBcAb was associated with advanced hepatic fibrosis in HIV+ persons Methodology: We conducted a cross-sectional study among HIV+ patients in the Veterans Aging Cohort Study Virtual Cohort who had available laboratory data to determine chronic HCV status and 5 serological patterns of HBV antibodies: 1) sole HBcAb, 2) resolved HBV infection (HBcAb+/HBsAb+), 3) no evidence of HBV infection or vaccination (non-immune HBV), 4) HbsAb+ only, and 5) active HBV infection (HBsAg+). The main outcome was advanced hepatic fibrosis determined by FIB-4 >3.25 and APRI>2.0. Laboratory data to determine outcomes were obtained within +/- 1 year of the earliest time that complete serological data to define HBV and HCV serostatus were available. Logistic regression was used to determine adjusted odds ratios (ORs) of advanced fibrosis. Results: Among 18,145 HIV+ patients (6,798 with and 11,347 without chronic HCV), sole HBcAb was more common in patients with chronic HCV than without (40% vs 13%; p<0.01). As shown in the table, compared with patients who were non-immune, HCV+ patients with sole HBcAb had a higher OR for advanced hepatic fibrosis by FIB-4 (OR 1.32, 1.09-1.60) but not APRI (OR 1.15, 0.92-1.44). In addition (data not shown), when compared to patients with resolved HBV or who were HBsAb+ only, patients with sole HBcAb had higher OR for advanced hepatic fibrosis by both FIB-4 (OR 1.34, 1.15-1.58 and 1.65, 1.20-2.28, respectively) and APRI (OR 1.40, 1.15-1.71 and 1.88, 1.25-2.84, respectively). No association between sole HBcAb status and advanced hepatic fibrosis was seen among HCV- patients. Patients with active HBV had a higher prevalence of advanced hepatic fibrosis than did patients with any other HBV serological pattern, regardless of HCV status. Conclusions: HIV+/HCV+ persons with sole HBcAb have evidence of a higher prevalence of advanced hepatic fibrosis, as assessed by FIB-4 or APRI scores, than persons who are non-immune to HBV, who have resolved HBV, or who are HbsAb+ only. These findings suggest that persons with sole HBcAb may be at increased risk of clinical liver complications, and are consistent with prior studies showing an increased prevalence of occult HBV infection in such individuals.